tDCS to Decrease Opioid Relapse (UH3)

Description

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

Conditions

Opioid Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

tDCS to Decrease Opioid Relapse (UH3)

tDCS to Decrease Opioid Relapse (UH3)

Condition
Opioid Use Disorder
Intervention / Treatment

-

Contacts and Locations

Providence

Butler Hospital, Providence, Rhode Island, United States, 02906

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. current opioid dependence
  • 2. between 21-60 years of age
  • 3. recent initiation of buprenorphine or methadone (≤30days)
  • 4. enrolled in Butler Hospital's Alcohol and Drug Inpatient Unit, Alcohol and Drug Partial Hospital Treatment Program, Intensive Outpatient Services, or Outpatient Services at Butler Hospital OR receive opioid-treatment services in the community.
  • 1. current diagnosis of organic brain disorder (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis, intracranial mass/infection, hydrocephalus)
  • 2. bipolar, schizophrenia, schizoaffective, or schizophreniform disorder, or current psychosis associated with any disorder
  • 3. current suicidality
  • 4. evidence of significant neurocognitive dysfunction
  • 5. conditions associated with heightened tDCS risks, e.g., seizure disorder, nonremovable intracranial metal objects (other than dental fillings and dental implants), skin disease or active lesions on the scalp, migraine/other headache disorder with significant active symptoms, traumatic brain injury or skull fracture within the past year, any implanted medical devices or device components that can interact with electromagnetic fields or are controlled by physiological signals
  • 6. probation/parole requirements or an upcoming move that might interfere with protocol participation
  • 7. planning to terminate buprenorphine or methadone in less than 3 months
  • 8. current pregnancy or plan to become pregnant in the next month.

Ages Eligible for Study

21 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Butler Hospital,

Abrantes Abrantes, Ph.D., PRINCIPAL_INVESTIGATOR, Butler Hospital

Michael Stein, M.D., PRINCIPAL_INVESTIGATOR, Boston University

Study Record Dates

2026-12-31